A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients

This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.

Inclusion Criteria:

• Written informed consent.
• Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).
• No prior therapy or inadequate response to therapy for hepatitis C.
• Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.

Exclusion Criteria:

• Use of other investigational drugs within at least 30 days of enrollment
• Women of child-bearing potential.

Other protocol-defined inclusion/exclusion criteria apply